Monoclonal gammopathy and smoldering multiple myeloma: Diagnosis, staging, prognosis, management

Recent Results in Cancer Research

Volumn 183, Issue , 2011, Pages 113-131

  Hillengass, Jens ^a   Moehler, Thomas ^a,b   Hundemer, Michael ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b i3 Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKYLATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 1; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; PREDNISONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CYTOGENETICS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR GENETICS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SEX RATIO; SMOLDERING MULTIPLE MYELOMA;

BONE MARROW; CHROMOSOME ABERRATIONS; CLONE CELLS; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMA CELLS; PROGNOSIS; RISK FACTORS;

EID: 79955619424     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-85772-3_6     Document Type: Review

References (63)

1. Alexanian R, Barlogie B, Dixon D (1988) Prognosis of asymptomatic multiple myeloma. Arch Intern Med 148:1963-1965
2. Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB (2008) Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112:3122-3125
3. Bauerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Christiane H, Wagner-Gund B, Neben K, Kauczor HU, Goldschmidt H, Delorme S (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 252:477-485
4. Baur A, Stabler A, Nagel D, Lamerz R, Bartl R, Hiller E, Wendtner C, Bachner F, Reiser M (2002) Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 95:1334-1345
5. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28-38
6. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103:3175-3184 (Pubitemid 38451696)
7. Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ III, Rajkumar SV (2010) Impact of optimal follow-up of monoclonal gammopathy of undetermined significance (MGUS) on early diagnosis and prevention of myeloma-related complications. Blood 116(12):2019-2025
8. Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, Vives-Corrons JL, Montserrat E (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 81:391-394
9. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA (2010) Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28:690-697
10. Brousseau M, Leleu X, Gerard J, Gastinne T, Godon A, Genevieve F, Dib M, Lai JL, Facon T, Zandecki M (2007) Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res 13:6026-6031 (Pubitemid 350075058)
11. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E (2002) Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 20:1625-1634 (Pubitemid 34260544)
12. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM (2007) Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20:571-596 (Pubitemid 350215376)
13. Corso A, Ferretti E, Lazzarino M (2005) Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 10:215-224 (Pubitemid 41801138)
14. Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B (1998) Anti-myeloma activity of pamidronate in vivo. Br J Haematol 103:530-532 (Pubitemid 28522463)
15. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R (1993) Risk of disease progression in asymptomatic multiple myeloma. Am J Med 94:57-61 (Pubitemid 23021172)
16. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ III, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:785-789
17. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ III, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV (2010) Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375:1721-1728
18. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B (2003) Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 4(6):379-398
19. Facon T, Menard JF, Michaux JL, Euller-Ziegler L, Bernard JF, Grosbois B, Daragon A, Azais I, Courouble Y, Kaplan G (1995) Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myelome (GERM). Am J Hematol 48:71-75
20. Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G, Moss P (2005) CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106:4217-4224 (Pubitemid 41775929)
21. Goodyear OC, Pratt G, McLarnon A, Cook M, Piper K, Moss P (2008) Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood 112:3362-3372
22. Grass S, Preuss KD, Ahlgrimm M, Fadle N, Regitz E, Pfoehler C, Murawski N, Pfreundschuh M (2009) Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol 10:950-956
23. Grass S, Preuss KD, Pfreundschuh M (2010) Autosomal-dominant inheritance of hyperphosphorylated paratarg-7. Lancet Oncol 11:12
24. Grignani G, Gobbi PG, Formisano R, Pieresca C, Ucci G, Brugnatelli S, Riccardi A, Ascari E (1996) A prognostic index for multiple myeloma. Br J Cancer 73:1101-1107 (Pubitemid 26131232)
25. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13:1503-1510 (Pubitemid 46450441)
26. Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28:1606-1610
27. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J (1990) Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. Br J Haematol 74:185-191 (Pubitemid 20041094)
28. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J (1993) Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 50:95-102 (Pubitemid 23061274)
29. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Reme T, De VJ, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Mohler T (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114:128-143
30. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M (2007) Prevalence of monoclonal gammopathy of undetermined significance: study of 52, 802 persons in Nagasaki City, Japan. Mayo Clin Proc 82:1474-1479 (Pubitemid 350211694)
31. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C (2006) Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20:1130-1137 (Pubitemid 43797308)
32. Kyle RA, Greipp PR (1980) Smoldering Multiple Myeloma.N Engl J Med 302:1347-1349
33. Kyle RA, Rajkumar SV (2007) Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 20:637-664 (Pubitemid 350215374)
34. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3-9
35. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569 (Pubitemid 34438817)
36. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ III (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362-1369
37. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ III, Rajkumar SV (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582-2590 (Pubitemid 46961003)
38. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San MJ, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121-1127
39. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904-906 (Pubitemid 43156286)
40. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, Biritwum RB, Tettey Y, Adjei AA, Larson DR, Dispenzieri A, Melton LJ III, Goldin LR, McMaster ML, Caporaso NE, Rajkumar SV (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468-1473 (Pubitemid 350211693)
41. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412-5417
42. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103:2308-2315 (Pubitemid 38326251)
43. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84:114-122
44. Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, Frija J, Brouet JC, Fermand JP (1999) Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 104:723-729 (Pubitemid 29143489)
45. Martin A, Garcia-Sanz R, Hernandez J, Blade J, Suquia B, Fernandez-Calvo J, Gonzalez M, Mateo G, Orfao A, San Miguel JF (2002) Pamidronate induces bone formation in patients with smoldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 118:239-242 (Pubitemid 34779542)
46. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM (2003) Pamidronate for early-stage, untreated myeloma. J Clin Oncol 21:3177-3178
47. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, Lust JA, Dispenzieri A, Greipp PR, Kyle RA, Rajkumar SV (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106:2276-2279 (Pubitemid 41510796)
48. Perez-Persona E, Mateo G, Garcia-Sanz R, Mateos MV, de Las HN, de Coca AG, Hernandez JM, Galende J, Martin-Nunez G, Barez A, Alonso JM, Martin A, Lopez-Berges C, Orfao A, San Miguel JF, Vidriales MB (2010) Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 148:110-114
49. Preuss KD, Pfreundschuh M, Ahlgrimm M, Fadle N, Regitz E, Murawski N, Grass S (2009) A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer 125:656-661
50. Rajkumar SV (2009) Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 15:5606-5608
51. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE (2001) Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15:1274-1276 (Pubitemid 32776453)
52. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17:775-779 (Pubitemid 36519375)
53. Rajkumar SV et al (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 106:812-817 (Pubitemid 41076419)
54. Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, De PA, Barbarano L, Di SM, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E (2000) Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 82:1254-1260 (Pubitemid 30145341)
55. Roodman GD (2002) Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17:1921-1925
56. Rosinol L, Blade J, Esteve J, Aymerich M, Rozman M, Montoto S, Gine E, Nadal E, Filella X, Queralt R, Carrio A, Montserrat E (2003) Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 123:631-636 (Pubitemid 37468059)
57. Ross FM, Chiecchio L, Dagrada G, Protheroe RK, Stockley DM, Harrison CJ, Cross NC, Szubert AJ, Drayson MT, Morgan GJ (2010) The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95:1221-1225
58. Tsubaki M, Kato C, Manno M, Ogaki M, Satou T, Itoh T, Kusunoki T, Tanimori Y, Fujiwara K, Matsuoka H, Nishida S (2007) Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem 304:53-60 (Pubitemid 47456852)
59. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121-1128 (Pubitemid 46596765)
60. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R (1997) Prognostic features of asymptomatic multiple myeloma. Br J Haematol 97:810-814 (Pubitemid 27321380)
61. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19
62. Wisloff F, Andersen P, Andersson TR, Brandt E, Eika C, Fjaestad K, Gronvold T, Holm B, Lovasen K, Tjonnfjord GE (1991) Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II. Eur J Haematol 47:338-341
63. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757 (Pubitemid 34533050)